Who are ICM ADX-2191 injection's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/icm-adx-2191-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ICM ADX-2191 injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ICM ADX-2191 injection (ICM ADX-2191 injection) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aldehyde modulator. Area: Immunology.

phase 3 Aldehyde modulator Aldehyde dehydrogenase (ALDH) / reactive aldehydes Immunology Small molecule Live · refreshed every 30 min

Target snapshot

ICM ADX-2191 injection (ICM ADX-2191 injection) — Aldeyra Therapeutics, Inc.. ADX-2191 is a reactive aldehyde species that inhibits aldehyde dehydrogenase (ALDH) to modulate immune and inflammatory responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ICM ADX-2191 injection TARGET	ICM ADX-2191 injection	Aldeyra Therapeutics, Inc.	phase 3	Aldehyde modulator	Aldehyde dehydrogenase (ALDH) / reactive aldehydes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aldehyde modulator class)

Aldeyra Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ICM ADX-2191 injection — Competitive Intelligence Brief. https://druglandscape.com/ci/icm-adx-2191-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing